The global AL amyloidosis therapeutics market is slated to reach a valuation of US$ 2.25 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion.
The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition. The AL amyloidosis outlook was dismal prior to effective therapy for the fundamental plasma cell dyscrasia, with an average AL amyloidosis life expectancy of almost 13 months and to just 6 months for individuals with symptomatic cardiac dysfunction. Indicators of myocardial cell destruction and heart failure, that are exceedingly sensitive to cardiac dysfunction in amyloidosis, are the main focus of present AL amyloidosis staging techniques.
The purpose of AL amyloidosis therapy is to quickly decrease the plasma cell clone in order to increase amyloid reabsorption as well as restore organ function, hence enhancing patients' QOL, heart function, and survival. In the right patients, chemotherapy (both low and high dose) combined with autologous hematopoietic stem cell transplantation (ASCT) significantly lowers the formation of amyloid light chains. Melphalan, bortezomib and dexamethasone-based regimens should be used to treat patients who are ineligible for ASCT.
As one AL amyloidosis therapeutic approach, the National Comprehensive Cancer Network suggests high-dose melphalan followed by ASCT. Treatment for AL amyloidosis is very customized and should be focused on hematologic as well as cardiac response indicators as well as organ dysfunction, age, and regimen toxicity. Alkylator-based chemotherapy is beneficial for around two thirds of patients. Also, there are tests being conducted to determine the optimum way to use novel agents. Such developments are expected to people the demand in the market from 2023 to 2033.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | US$ 2.1 billion |
| Expected Market Value (2023) | US$ 2.25 billion |
| Projected Forecast Value (2033) | US$ 4.56 billion |
| Global Growth Rate (2023 to 2033) | 7.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global AL amyloidosis therapeutics market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. Although this condition is more common in adults above the age of 60 years and older, the growing geriatric population in both developed and emerging nations is also driving the demand in the global AL amyloidosis therapeutics market.
Also, the market for AL amyloidosis treatments is accelerating due to increased governmental and private sector funding, research, and development efforts. The development of healthcare technology and growing public awareness of rare illnesses are expected to support market expansion in the years to come. As a result, the global AL amyloidosis therapeutics market is expected to forecast a CAGR over 8% from 2023 to 2033.
Various biological advancements used in this therapy is driving the market expansion
The market for AL amyloidosis therapeutics is largely being driven by the rise in incidences of mutations in blood cell DNA and the prevalence of underlying plasma cell illnesses such as monoclonal gammopathy and multiple myeloma of uncertain significance.
Also, the widespread use of amyloid stabilizers, which stabilize the amyloid protein and stop it from building up in tissues and organs, is supporting the market's expansion. Moreover, the increasing use of innovative treatments that target the underlying causes of AL amyloidosis, such as immunomodulatory medications, proteasome inhibitors, monoclonal antibodies, etc. has considerably increased patient response times and lengthened progression-free life. This in turn is serving as yet another important component that promotes development.
The market is also expanding owing to the rising demand for high-dose chemotherapy, accompanied by autologous transplantation of stem cells, as a therapeutic option for patients admitted with AL amyloidosis. This therapy tries to enhance organ function by removing aberrant cells that generate amyloid protein. Moreover, continual improvements in diagnostic methods, such as the development of serum-free light chain tests as well as mass spectrometry, have made it possible to make diagnoses sooner, enabling quicker treatment to begin and improved control of disease-related problems. Hence, the market for AL amyloidosis therapeutics is anticipated to grow throughout the course of the projected period.
Principal Consultant
Lack of information and clinical studies is expected to impede the market growth
There is a shortage of epidemiological information on AL amyloidosis, and retrospective analysis reduces the validity of the data, which limits the market's potential growth. Additionally, the complex heterogeneity of the illnesses delays diagnosis, leading to severe disease (organ malfunction, including kidney, heart, and liver), lowering survival rates for AL amyloidosis, and acting as a roadblock to the expansion of the AL amyloidosis therapeutics market.
Clinical studies for AL amyloidosis therapeutics are also difficult to conduct successfully because of low patient recruitment as well as a lack of strictly delineated new outcomes. The participation of the kidney and heart systems results in expensive medical care. Moreover, the anticipated releases will probably cost more than myeloma-based medications, which may limit the accessibility and affordability of the AL amyloidosis therapies. Additionally, the function of upfront ASCT in various eligible patients has to be addressed in the era of daratumumab-based therapy. The aforementioned issues thus restrict the growth of the AL amyloidosis therapeutics market.
Rising incidence of amyloidosis cases along with innovative products will boost the growth
During the forecast period, the North American market for AL amyloidosis therapeutics is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate with a robust CAGR of 7.9% from 2023 to 2033.
The adoption of innovative therapies surged as a result of the prospective release of pipeline medications, and its dominating market share is also largely due to the high expense of healthcare in the United States. Around 3,900 new instances of AL amyloidosis are detected each year in the United States, making it the most prevalent kind.
This disease variant's diagnostic age is often in the mid-60s. Its yearly incidence in North American nations is roughly 15 instances per million persons, or about one-fifth that of myeloma, a blood cancer brought on by clonal plasma cells found in the bone marrow. Moreover, it can be challenging to diagnose since symptoms including weariness, paresthesia, edema, and weight loss frequently coexist with those of other prevalent illnesses. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.
Enhanced healthcare facilities and strong patient pool to accelerate growth
During the forecast period, the Asia Pacific market for AL amyloidosis therapeutics is expected to garner a steady CAGR of 7.6%. The Asia Pacific AL amyloidosis therapeutics market is anticipated to grow quickly throughout the time of forecasting. This is because two of the three late-stage medications have received approval in Asia Pacific to treat amyloidosis. Due to supportive government policies, enhanced healthcare infrastructure, and greater investment, emerging markets for amyloidosis, such as China and India, are anticipated to have enticing development throughout the projection period.
The strong need for economical healthcare in these nations with big populations and low per capita incomes will fuel the growth of chemotherapy generic versions in this market. Alternatives for curative treatments with increased effectiveness are desperately needed. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The chemotherapy segment will gain the dominant market share
Over the course of the forecast period, the chemotherapy segment by treatment type is anticipated to occupy a significant share of the global AL amyloidosis therapeutics market. In 2023, this category is anticipated to dominate with a 53% revenue share.
Anti-cancer treatments or chemotherapy are used to treat AL amyloidosis because they slow the proliferation of the aberrant cells that produce amyloid. Such factors are expected to accelerate the growth prospects for AL amyloidosis therapeutics from 2023 to 2033.
Hospital pharmacies segment will demand during the forecast period
Future Market Insights' study indicates that the hospital pharmacy segment would expand throughout the projected period. From 2023 to 2033, it is predicted that this market segment would have a 25% share of the global market.
Patients who are diagnosed with AL amyloidosis are mostly being treated in the hospitals under the supervision of the specialized doctors. With such patients, no doctor takes the risk of the treating them at home. Hence, as the treatment is being conducted in the hospitals itself, most of the medications and therapies are provided by the hospitals.
The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
The launch of Darzalex Faspro by Genmab as well as Janssen Biotech, as well as AstraZeneca's purchase of Caelum Biosciences in 2021, are two examples of how significant industry players are increasing their understanding of the disease and working together. One of the main drivers of the AL amyloidosis therapeutics market growth is the strong pipeline with innovative, first-in-class medicines for the treatment of the disease.
Some of the important developments of the key players of the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.3% from 2023 to 2033 |
| Market value in 2023 | US$ 2.25 billion |
| Market value in 2033 | US$ 4.56 billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The market is valued at US$ 2.25 billion in 2023.
The market rose at a 5.2% CAGR from 2018 to 2022.
The market is forecast to secure a CAGR of 7.3% through 2033.
The market is expected to reach US$ 4.56 billion by 2033.
North America is expected to accumulate a CAGR of 7.9% until 2033.
1. Executive Summary | AL Amyloidosis Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Chemotherapy 5.3.2. Supportive Care 5.3.3. Surgery 5.3.4. Stem Cell Transplant 5.3.5. Targeted Therapy 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drugs 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drugs, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drugs, 2023 to 2033 6.3.1. Transthyretin Transport Inhibitor 6.3.2. Immunomodulatory Drugs 6.3.3. Monoclonal Antibodies 6.3.4. Proteasome Inhibitors 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Drugs, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drugs, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Drugs 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Drugs 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Drugs 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Drugs 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. United kingdom 11.2.1.2. Spain 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. France 11.2.1.6. Rest of Europe 11.2.2. By Treatment 11.2.3. By Drugs 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Drugs 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. India 12.2.1.4. South Korea 12.2.1.5. Rest of Asia Pacific 12.2.2. By Treatment 12.2.3. By Drugs 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Drugs 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. South Africa 13.2.1.2. GCC Countries 13.2.1.3. Rest of Middle East and Africa 13.2.2. By Treatment 13.2.3. By Drugs 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Drugs 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Treatment 14.1.2.2. By Drugs 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Treatment 14.2.2.2. By Drugs 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Treatment 14.3.2.2. By Drugs 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Treatment 14.4.2.2. By Drugs 14.4.2.3. By Distribution Channel 14.5. United kingdom 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Treatment 14.5.2.2. By Drugs 14.5.2.3. By Distribution Channel 14.6. Spain 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Treatment 14.6.2.2. By Drugs 14.6.2.3. By Distribution Channel 14.7. Germany 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Treatment 14.7.2.2. By Drugs 14.7.2.3. By Distribution Channel 14.8. Italy 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Treatment 14.8.2.2. By Drugs 14.8.2.3. By Distribution Channel 14.9. France 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Treatment 14.9.2.2. By Drugs 14.9.2.3. By Distribution Channel 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Treatment 14.10.2.2. By Drugs 14.10.2.3. By Distribution Channel 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Treatment 14.11.2.2. By Drugs 14.11.2.3. By Distribution Channel 14.12. India 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Treatment 14.12.2.2. By Drugs 14.12.2.3. By Distribution Channel 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Treatment 14.13.2.2. By Drugs 14.13.2.3. By Distribution Channel 14.14. South Africa 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Treatment 14.14.2.2. By Drugs 14.14.2.3. By Distribution Channel 14.15. GCC Countries 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Treatment 14.15.2.2. By Drugs 14.15.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Treatment 15.3.3. By Drugs 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Janssen Pharmaceutical 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Prothena 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Alexion Pharmaceuticals 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Oncopeptides AB 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Bristol-Myers Squibb 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. GlaxoSmithKline Pharmaceuticals Ltd 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Celgene Corp 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Eidos Therapeutics, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Corino Therapeutics, Inc. 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Spectrum Pharmaceuticals, Inc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
AL Amyloidosis Therapeutics Market
